• CBT-101 is an oral agent that targets the epithelial to mesenchymal transition (EMT) pathway that is dysregulated in several tumors. It is a specific inhibitor of the c-Met receptor.
  • c-Met, which is also known as the hepatocyte growth factor receptor, or HGFR, is a signaling pathway that has specific roles in normal mammalian growth and development. However, the HGFR pathway has also been shown to function abnormally in a range of different cancers, primarily through c-Met gene amplification, c-Met over-expression and gene mutations. The aberrant activation of c-Met has been demonstrated to be correlated in many cancer indications, including kidney, lung, gastric, colorectal, esophageal and brain cancer, and plays a major role in cancer pathogenesis including tumor growth, survival, invasions, and metastasis.
  • CBT-101 is being tested in a first-in-human Phase 1 clinical trial in China by our China partner, Beijing Pearl Biotechnology Co. Ltd., and a Phase 1 trial is planned to be initiated in US. We retain world-wide rights to this drug outside of China.